Senomorphics and senolytics both target senescent cells, but they do opposite things to them. Senolytics kill senescent cells outright. Senomorphics leave the cells alive and instead suppress the inflammatory signals they release. That distinction, kill versus quiet, is the whole comparison, and it explains why the two drug classes show up in different kinds of trials, carry different risk profiles, and answer different questions about aging.
This page exists because the two terms get confused constantly, usually alongside senolysis and senolytics, a related but different distinction. That page covers the process (senolysis) versus the compound class that triggers it (senolytics). This page covers senolytics versus a separate compound class entirely: senomorphics.
The One-Sentence Version
Senolytics selectively induce the death of senescent cells. Senomorphics modulate the harmful behavior of senescent cells, especially the senescence-associated secretory phenotype (SASP), without killing them.
What Senescent Cells Actually Do
A senescent cell has permanently stopped dividing but has not died. Instead of clearing out the way most damaged cells eventually do, it lingers in tissue and secretes a mix of inflammatory cytokines, growth factors, and enzymes collectively called the SASP. That secretion is what causes most of the trouble: it can damage nearby healthy cells, recruit immune cells that cause more inflammation, and contribute to the low-grade chronic inflammation researchers call inflammaging. See Senescent Cells and SASP for the fuller definitions.
Two different intervention strategies follow from that biology. Remove the cell, and its secretions stop because the source is gone. Or leave the cell in place and turn down what it secretes. Senolytics take the first approach. Senomorphics take the second.
How Senolytics Work
Senolytics selectively push senescent cells into apoptosis, programmed cell death, while sparing healthy cells nearby. They typically work by disabling the anti-apoptotic pathways senescent cells depend on to resist the death signals that would normally clear them. Once those defenses are disabled, the cell dies and the tissue's immune system clears the debris.
The best-studied senolytic combination is dasatinib plus quercetin, usually written D+Q. It is currently the only senolytic combination shown in human trials to clear senescent cells about as effectively as it does in mice, and it has been tested in small trials for osteoporosis, diabetic kidney disease, idiopathic pulmonary fibrosis, and mild cognitive impairment. A phase 2 trial of D+Q for osteoporosis and a 2025 pilot trial in older adults with cognitive decline are both examples of that early human work. Fisetin, a flavonoid studied at the Mayo Clinic as a senolytic, is the other most-discussed candidate. See Senolytics in the directory for the full therapy profile.
How Senomorphics Work
Senomorphics target the signaling pathways that drive SASP production rather than the cell itself. The SASP is regulated by several stress-response pathways, most notably NF-kB, mTOR, and JAK/STAT, and senomorphic compounds interrupt one or more of those pathways to quiet the inflammatory output without triggering cell death.
Three drugs illustrate the mechanism, and all three are already approved for other conditions rather than being purpose-built senomorphics:
- Rapamycin, an mTOR inhibitor, has been shown to suppress SASP production in preclinical models by interfering with translation of IL-1a, an upstream driver of the SASP cascade, according to research published in the journal Aging Cell. It is covered on this site as a longevity intervention in its own right; see the mTOR inhibition and rapamycin directory entry.
- Metformin, a standard type 2 diabetes drug, has been shown to reduce SASP secretion in multiple senescent cell types in laboratory studies, including endothelial cells exposed to inflammatory stress.
- Ruxolitinib, an FDA-approved JAK1/2 inhibitor used for certain blood disorders, has been shown in laboratory studies to reduce SASP components including IL-6 and MCP-1 in senescent preadipocytes and endothelial cells.
None of these three is approved as a senomorphic for aging. They are approved drugs for other conditions whose senomorphic effect has been observed in research settings, which is an important distinction from a compound purpose-built and approved for this use.
Senomorphics vs. Senolytics: Side by Side
| Senolytics | Senomorphics | |
|---|---|---|
| What happens to the cell | Killed via induced apoptosis | Left alive; secretions suppressed |
| Primary mechanism | Disables anti-apoptotic pathways senescent cells rely on to survive | Interrupts NF-kB, mTOR, or JAK/STAT signaling that drives SASP output |
| Dosing pattern studied | Intermittent, "hit and run" (short courses, repeated periodically) | Typically continuous or chronic dosing to keep SASP suppressed |
| Leading examples | Dasatinib plus quercetin, fisetin | Rapamycin, metformin, ruxolitinib |
| Human trial status | Small trials in osteoporosis, IPF, diabetic kidney disease, cognitive decline | Human data mostly from other-indication trials (diabetes, transplant, myelofibrosis) rather than aging-specific trials |
| Theoretical risk if it works | Loses whatever beneficial role senescent cells play in wound healing and tumor suppression | Cells remain in tissue indefinitely, still present but quieter |
Why the Distinction Matters for Readers
Marketing copy sometimes uses senolytic loosely to describe any anti-aging compound that touches senescent cells, which blurs a real mechanistic difference. A supplement that claims to be senolytic but works through a senomorphic mechanism, or vice versa, is not automatically wrong. It is just imprecise in a way that makes the underlying evidence harder to evaluate. Knowing which mechanism a product claims lets you check the right research: apoptosis and cell-clearance studies for senolytic claims, SASP and cytokine-suppression studies for senomorphic ones.
The two approaches are not mutually exclusive as research directions. Some researchers are studying combined senolytic-plus-senomorphic strategies on the theory that clearing some senescent cells while quieting the ones that remain could address more of the SASP's damage than either approach alone, though that combined strategy remains at the research stage rather than anything close to clinical practice.
What Neither Approach Has Proven Yet
Both classes share the same evidence gap: mechanism and biomarker changes are not the same as demonstrated healthspan or lifespan benefit in humans. Preclinical models, mostly mice, show lifespan extension and reduced age-related pathology from both senolytic and senomorphic interventions. Human trials so far are small, short, and focused on specific conditions or biomarkers rather than aging as a whole. Neither senolytics nor senomorphics are FDA-approved treatments for aging, and the drugs discussed here that do have FDA approval are approved for the conditions named, not for senescence control.
Common Questions
What is the difference between senolytics and senomorphics?
Senolytics kill senescent cells through induced apoptosis. Senomorphics leave the cells alive but suppress the inflammatory SASP signals they secrete. Both aim to reduce the tissue damage senescent cells cause, through opposite mechanisms.
Is rapamycin a senolytic or a senomorphic?
Rapamycin is studied as a senomorphic. As an mTOR inhibitor, it has been shown in preclinical research to suppress SASP output without killing the senescent cells themselves.
Are senomorphics safer than senolytics?
Not necessarily. Because senomorphics require ongoing or chronic dosing to keep suppressing SASP output, they carry different long-term exposure considerations than the intermittent dosing studied for senolytics. Neither class has enough long-term human safety data in the context of aging specifically to make a general safety comparison.
Can senolytics and senomorphics be used together?
Researchers are exploring combined strategies, clearing some senescent cells while suppressing the SASP of those that remain, but this remains an active research question rather than an established or approved protocol.
Is metformin a senolytic drug?
No. Metformin has been studied for a senomorphic effect, reducing SASP secretion in senescent cells, not for killing senescent cells outright.
For the compound-versus-process distinction, see Senolysis vs. Senolytics. For the fuller senolytics research overview, see Senolytics: Clearing Senescent Cells in Longevity Research and the Senolytics directory profile.